anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cold Packs (Cold Pack, CP); Slika gel packs are the most commonly used modalities in clinics. Special silicate gel impregnated with water in a soft rubber envelope is stored in coolers whose temperature is maintained between -12.2 ° C and 9.4 ° C . There are different sizes and shapes. Since it does not lose its softness when it is cooled, it adapts well to the folds of the body. By putting a towel between the skin and the package, a homogeneous cooling is tried to be achieved, hygiene is provided and it is easier to tolerate the feeling of extreme cold felt in the first contact of the cold package. It can be applied for a relatively long time without losing its cold due to its low conductivity. Significant increase in package temperature is seen from the 15th minute of the application. It is stated that it decreases the skin temperature up to 10 ° C and keeps it at 20 ° C-30 ° C for 3 hours depending on the room temperature. They can be used repeatedly by cooling .

Intensive cold application for 12-15 minutes is enough to reduce pain and muscle spasm . It has also been shown that a cold application over 30 minutes can cause cold bite and nerve problems . However, in practical applications, cold appears to vary between 15-30 minutes for pain, muscle spasm and edema . In a review made by Auley regarding cryotherapy treatments; ice application has been shown to be used in 5 to 85 minutes in many studies. They said that cold application does not have a specified frequency and duration, but repeated 10 minutes of cold application is effective. In addition, it has been reported that there is evidence of a slightly less drop from 10 minutes to 20 minutes while the temperature drops in the first 10 minutes .

In animal studies performed in vitro, although muscle tissue has reported high resistance to strain after cooling, direct mechanical responses to muscles in human studies There is only one study that evaluates. In this study carried out by Mustalampi et al., Parameter measurements indicating the mechanical properties of the muscle immediately after applying the cold pack applied locally to the quadriceps muscle for 20 minutes and after 15 minutes. As a result of the study, the muscle has become stiffer, less elastic in terms of mechanical properties and it has been shown that these changes do not completely recover after 15 minutes. It was not observed when it was reinstated after fifteen minutes.

In the light of this information, in the current study proposal; the investigators aim to investigate the acute effect (0 min, 5 min, 10 min, 15 min, 20 min and 30 min) of the cold pack therapy on the mechanical properties of the quadriceps muscle in healthy people for different periods (10-12-15-20 minutes).
Polyolefin film with a mat finish comprises at least two coextruded layers; an upper mat finish layer comprising high density polyethylene, polypropylene or blends thereof and a second layer comprising low density polyethylene, linear low density polyethylene or blends thereof. The film is prepd. by coextrusion of an external layer comprising high density polyethylene, polypropylene or blends thereof and an internal layer comprising low density polyethylene, linear low density polyethylene or blends thereof. The extrusion process comprises passage of the coextruded layers from feed zone to an extruder die through temp. control zones where the external layer passing through the temp. control zones from the feed zone is heated more rapidly to a higher temp. than the corresp. internal layer in the corresp. temp. control zone
The present invention relates to a solid preparation, a preparation method thereof and an application thereof, and the solid preparation is formed by adding traditional Chinese medicine and natural plant extraction ingredients into isomalt as a main raw material. The isomalt has the advantages of mildly sweet taste, good fragrance transfer, low heat, no caries generation and low moisture absorption, and the traditional Chinese medicine and the natural plant solid preparation made from the isomalt has the advantages of good forming, high hardness, tasting slipperiness, purely sweet taste, good mouth feel, good surface lightness and low moisture absorption. A final product has outstanding storage stability. The present invention also discovers the preparation method, and in the preparation method, no coking phenomenon is generated when the traditional Chinese medicine and plant extracts are added into syrup. A forming process can be carried out without coking phenomenon under high temperature, and the forming process under the high temperature is good for rapidly removing water content by baking and rapidly forming. The present invention enhances work efficiency, and agricultural industrialization can be conveniently carried out.
A healthcare information system, method and computer program product are provided to receive, process and output healthcare data in compliance with data use restrictions associated with the healthcare data, even in instances in which data projections are assembled from the data elements. In regards to a healthcare information system, processing circuitry is configured to assemble the data projection from a plurality of data elements. At least some data elements have different data use restrictions associated therewith. The processing circuitry is also configured to determine a combined data use restriction for the data projection based upon the data use restrictions of the data elements from which the data projection is assembled. The processing circuitry is further configured to associate metadata with the data projection including the combined data use restriction. Further, the processing circuitry is configured to control access to the data projection in accordance with the combined data use restriction.
The present invention relates to a preparation of Chinese herbal medicament for treating cold injury, various indurations, swelling, and pain and a preparing method thereof, which belongs to the technical field of medicaments and is used for achieving the purposes of performing special effects on I cold injury and II cold injury and treating indurations, swelling and pain due to various reasons. The present invention has the technical scheme that the preparation is prepared by refining lilac daphne, cassia bark and safflower as raw materials according to proportions by processes such as screening, soak, filtration, etc. The preparation quickly acts and has an exact therapeutic effect on treating the cold injury, traumatic injury, wrench, rheumatism bone pain, various indurations, surgical edema and stasis diseases. More than 80% of patients remove the swelling, the pain and the indurations after administration of 1 to 3 days by the clinical observation of thousands of cases. The preparation quickly absorbs edema stasis liquid and has a fast analgesic effect. The medicament is tincture. After coated in an affected position, the medicament is quickly absorbed by tissue for participating in humoral circulation. The absorbing process of the medicament is faster than that of paste, oil and powder. Patients can conveniently take the medicine. A remnant and dirt are not left in an administration position.
Patients in the intervention group will be contacted via SMS text message seven days, fourteen days and twenty-one days after surgery with the link request remaining open for 6 days until the next request is sent out. The exception being the last request link which will remain open until 30 days after surgery. In the requests patients are asked to submit a photo of their wound and complete the UKHSA wound surveillance questionnaire. Participants can also submit an image during the 30 days whenever they have a concern.
A composition, and methods of forming and using said composition, for the sustained release of biologically active, stabilized human growth hormone (hGH). The sustained release composition of this invention comprises a polymeric matrix of a biocompatible polymer and particles of biologically active, stabilized hGH, wherein said particles are dispersed within the biocompatible polymer. The method of the invention for producing a composition for the sustained release of biologically active hGH, includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, metal cation-stabilized hGH in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said hGH particles. The method for using a composition of the invention is a method for providing a therapeutically effective blood level of biologically active, non-aggregated hGH in a subject for a sustained period. In this method, a subject is administered an effective dose of the sustained release composition of the present invention. The method of using the sustained release composition of the present invention comprises providing a therapeutically effective blood level of biologically active, non-aggregated human growth hormone in a subject for a sustained period by administering to the subject a dose of said sustained release composition.
Participants who lost less than 2.5 percent (%) of their body weight initially will be randomized to a different type of intervention. One possibility could be that participants switch first-line treatment from a prescriptive strategy to the alternative (behavioral) as participants may need motivation or problem-solving.
A preparation method of a near infrared light excitation temperature sensitive nano preparation for tumor photo-thermal/chemotherapy relates to the field of biological medicine application. Chemotherapy is a conventional method for clinically treating tumors, however, the method has the problems of poor selectivity of chemotherapeutic drugs, large toxic and side effects, drug resistance and the like. Photothermal therapy is receiving attention due to the characteristics of convenient operation, no invasiveness, local selectivity, small drug resistance, small side effects, and the like. The photothermal/chemotherapy combined treatment can overcome the limitation of monotherapy, and in addition, the stimulus-responsive carrier can realize targeted delivery of the medicine, thereby improving the treatment efficiency. The gold nano cage is selected as a photo-thermal preparation, and the inside of the gold nano cage is filled with a temperature-sensitive material to carry out targeted delivery and controlled release on the chemotherapeutic drugs, and the gold nano cage shows photo-thermal activity and release behavior of the chemotherapeutic drugs after irradiation of near infrared light (808 nm). Therefore, the invention has important practical prospect and social value in the field of preparation of novel antitumor drugs.
NEW MATERIAL:A compound expressed by formula I (P is peptide residue having amino acid sequence of human calcitonin). USE:A remedy for hypercalcemia, Behcet's disease, etc. PREPARATION:For example, a microorganism, e.g. Escherichia coli, etc. is transformed with a plasmid containing a DNA containing a gene capable of coding a peptide expressed by formula II (n is a positive integer) and then cultivated in a culture medium to produce a fused protein containing the peptide expressed by formula II in the resultant culture. The above-mentioned fused protein is then treated with an enzyme, e.g. trypsin, etc., to afford the aimed human calcitonin precursor peptide expressed by formula I.
Compositions, methods for preparing and methods of using air-filled polymeric microcapsules for ultrasound imaging are disclosed. Air-encapsulating microcapsules are formed by ionotropically gelling synthetic polyelectrolytes such as poly(carboxylatophenoxy)phosphazene, poly(acrylic acid), poly(methacrylic acid) and methacrylic acid copolymers (Eudragit's) by contact with multivalent ions such as calcium ions. In the preferred embodiment, the average size of the microcapsules is less than seven μm so that they are suitable for injection intravenously. The polymeric microcapsules are stable to imaging and display high echogenicity, both in vitro and in vivo. Due to their in vivo stability their potential application is extended beyond vascular imaging to liver and renal diseases, fallopian tube diseases, detecting and characterizing tumor masses and tissues, and measuring peripheral blood velocity. The microcapsules can optionally be linked with ligands that minimize tissue adhesion or that target the microcapsules to specific regions.
The invention belongs to the technical field of biological medicine and biological detection and particularly relates to an epitope minimum motif peptide of P1, VP2 and VP4 structural proteins in a type O foot and mouth disease virus (FMDV) strain (O/BY/CHA/2010) and application of the epitope. Five linear epitope minimum motif peptides provided by the invention can be used as candidate epitope peptides for research and development of a novel recombinant multi-epitope peptide vaccine against type O FMDV and have amino acid sequences as shown in SEQ. ID NO.1-SEQ. ID NO.5. The invention also provides a candidate epitope for research of a detection antigen of a high-specificity and high-sensitivity recombinant multi-epitope peptide for diagnosing prevalence of the FMDV and the candidate epitope has amino acid sequences as shown in the SEQ. ID NO.6-SEQ. ID NO.10.
The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
Methods are provided herein to prevent a tumor recurrence in a subject, involving administering to the subject an agent that blocks the TGF-.beta.  signaling pathway. In one embodiment, the agent inhibits the immunosuppressive effects of TGF-.beta.. Also provided is a method of enhancing an immune respond in a subject to inhibit recurrence of a tumor by administering an agent which blocks the TGF-.beta. signaling pathway. A method of enhancing the activity of an immune cell to inhibit recurrence of a tumor by contacting a TGF-.beta. receptor-expressing cell with an agent which blocks the TGF-.beta.  signaling pathway is also provided, as are methods of screening for an agent that inhibits or measurably reduces the recurrence of a tumor.
Placebo monotherapy will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and placebo will be continued with ART until week 12.
A one-time use device to deliver preservative-free follicle stimulating hormone (FSH) solution is disclosed. The device includes a needle covered by a sliding needle shield, which covers the needle in all modes of the device. The device can be placed into a ready-to-use position in four or fewer user steps. The device has a knob for setting a desired dose of FSH. The knob includes longitudinally spaced elements respectively corresponding to the lock position and the seven or fewer discrete dosing positions. The device locks after one use and cannot be reused thereafter.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.   
No information is available from controlled clinical studies regarding the use of VOLTAREN® GEL in patients with advanced renal disease. Therefore, treatment with VOLTAREN® GEL is not recommended in patients with advanced renal disease. If VOLTAREN® GEL therapy is initiated, close monitoring of the patient's renal function is advisable.
One inhalation of 220 mcg A006 DPI. Total 220 mcg.
<P>PROBLEM TO BE SOLVED: To provide a curable composition for dental use by finding out the conditions of the composition satisfying both of a high bonding strength with dentinum and a suitable operable time and satisfying the conditions in the composition for curing a polymerizable monomer by reacting an oxidant with a reducing agent.  <P>SOLUTION: This separate package type curable composition for dental use is provided by containing a polymerizable monomer without having an acid group in the both of constituting pastes, also an acid group-containing polymerizable monomer in any one of the pastes, and further a hydroperoxide in any one of the pastes and a substituted thiourea compound in another paste, respectively, wherein, relational expressions 1.0≤X≤4.0 (i) and 3.2≤X×Y≤8.0 (ii) are satisfied in the case of setting the content of the hydroperoxide as the X pt.wt. based on the 100 pts.wt. total amount of the polymerizable monomer and the content of the substituted thiourea compound as the Y pt.wt. based on the 100 pts.wt. total amount of the polymerizable monomer.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention discloses a novel strain isolated and cultured from natural aweto, an artificial isolating and culturing method and a purpose thereof. The preservation number of the strain is CGMCC NO. 0706 and is characterized in that circular colonies are laid out with limits, annular patterns and wrinkles, are white at first and hoary late, have the diameter of 1.5 to 2.2cm and have taupe backs to purple brown backs after cultured for 10 days on a PDA culture medium under 25 DEG C; colorless hypha with branches has 1 to 2.5 mum of membranes; white spore stalk bundles with branches have the height of 0.5 to 3.5cm and the diameter of 0.2 to 1.5mm. The dry object of the present invention has a tumor inhibiting effect and can be used for preparing anti-tumor drugs. The present invention provides a novel strain which can be produced in industrialization for people, and the strain has the advantages of stability and anti-tumor activity and contains active components similar to the natural aweto. The strain provides a novel selectable species for people and also provides a novel raw material for anti-cancer drugs.
NEW MATERIAL:A compound expressed by formula I [R1 is H, 1-17C alkyl or 6-8C aryl; R2 and R3 are H or 1-3C alkyl; X(-) is halide ion, hydroxide ion or 1/2(sulfate) ion; n is a number of 1-10,000; T1 and T2 are halogen or formula II]. EXAMPLE:A compound expressed by formula III. USE:A flocculant, paper strengthening agent, textile dyeability improver, softening finish for hair, antistaic agent, electrically conductive agent, raw material for electrically conductive high polymer compositions (radical complex salts of polycations), and raw material for medicines, e.g. antimicrobial agent, antifungal agent, cholesterol-lowering agent, etc., and ion exchange resins. PREPARATION:A compound expressed by formula IV is reacted with p-xylylene dichloride in a solvent capable of dissolving both while heating to afford the aimed compound expressed by formula I. The above-mentioned compound expressed by formula I has good thermal stability and is capable of exhibiting good electric conductivity when applied to a radical anionic complex salt type electrically conductive high polymer composition of polycations without any skin irritancy.
The incidence of primary central nervous system lymphoma (PCNSL) has increased threefold in immunocompetent populations in recent years. Improvements in treatment, particularly involving combined modality therapy with chemotherapy and radiotherapy have been shown to augment patient survival with a median disease-free period of about 40 months. However, the combination of these two modalities often increases the risk for delayed neurotoxicity. There is a paucity of studies that have assessed neuropsychological functioning and quality of life in patients with PCNSL. The majority of studies reported performance status and survival rates, but systematic cognitive evaluations were only seldom included. Unfortunately, relying only on these variables does not adequately assess the more subtle cognitive impairments that most patients with brain tumors experience. Neuropsychological difficulties often interfere with disease free patients' ability to function at premorbid levels at work and at home. A study including neuropsychological evaluations of a relatively large group of patients with PCNSL who received combined modality treatments, and are in remission from their disease is planned. A follow-up assessment also will be performed in order to monitor performance over a specified period of time. The proposed study will also test the hypotheses that: (1) the presence of polymorphisms that influence methionine metabolism places PCNSL patients treated with chemotherapy alone or in combination with radiotherapy at risk for developing treatment-induced white matter disease and cognitive dysfunction; (2) the possession of the apolipoprotein E (APOE) є-4 allele is associated with the development of cognitive difficulties following treatment for PCNSL. Research in order to better understand the incidence, extent, and severity of treatment-induced neuropsychological impairments in patients with PCNSL is of utmost importance, given the recent increase in both the number of cases diagnosed and longterm survival. It is likely to provide valuable information regarding specific cognitive domains that should be addressed in the development of strategies for cognitive rehabilitation or other interventions that may be appropriate. The findings of this study will also be relevant for comparison with ongoing and future research investigating the potential neurocognitive sequelae of alternative treatment modalities for PCNSL (e.g., high-dose chemotherapy followed by peripheral blood progenitor cell (PBPC) transplant).
Polynucleotides encoding mammalian ECM signalling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signalling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signalling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signalling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signalling molecules. Further provided are methods for using mammalian ECM signalling molecules to screen for, and/or modulate, disorders associated with angiogenesis, chondrogenesis, and oncogenesis: ex vivo methods for using mammalian ECM signalling molecules to prepare blood products are also provided.
Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.